<code id='522BA61B0B'></code><style id='522BA61B0B'></style>
    • <acronym id='522BA61B0B'></acronym>
      <center id='522BA61B0B'><center id='522BA61B0B'><tfoot id='522BA61B0B'></tfoot></center><abbr id='522BA61B0B'><dir id='522BA61B0B'><tfoot id='522BA61B0B'></tfoot><noframes id='522BA61B0B'>

    • <optgroup id='522BA61B0B'><strike id='522BA61B0B'><sup id='522BA61B0B'></sup></strike><code id='522BA61B0B'></code></optgroup>
        1. <b id='522BA61B0B'><label id='522BA61B0B'><select id='522BA61B0B'><dt id='522BA61B0B'><span id='522BA61B0B'></span></dt></select></label></b><u id='522BA61B0B'></u>
          <i id='522BA61B0B'><strike id='522BA61B0B'><tt id='522BA61B0B'><pre id='522BA61B0B'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:4792
          Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y.
          A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

          Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

          An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.  

          advertisement

          This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          How one patient went off dialysis — and others can too
          How one patient went off dialysis — and others can too

          Melissa“Liddy”LawsonphotographedinSanFrancisco,whereshewashospitalizedfornearlysixmonths.ConstanzaHe

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Biogen shutters digital health group, ends Apple study, in cost cutting move

          RubyWallauforSTATBiogen,theiconicbutembattledbiotechfirm,isshutteringBiogenDigitalHealth,itsroughly1